Pfizer rules out mRNA COVID vaccine manufacturing in Australia

Pfizer rules out mRNA COVID vaccine manufacturing in Australia

with a shortage of pfizer jabs a bidding war is underway to manufacture this type of vaccine in australia this program can confirm csl luina bio and idt have all submitted proposals to the federal government a facility is expected to be up and running in the next three years but experts say it may hinge on one of the companies doing a deal with the world’s second biggest player moderna amelia terzon reports the pandemic has led to pioneering vaccines that only some can make there is not a country in the world today other than those who had that capacity before the pandemic began that has an end to end manufacturing capability for mrna vaccines not one now the federal government wants australia to have that capacity within three years there’s no facility in australia right now that can handle that kind of capacity the commonwealth is considering a dozen proposals including from csl lewina bio idt and by osina but getting manufacturing underway soon hinges on the two biggest vaccines we all know of the fisa moderna vaccines they’re super the effective they’re fantastic but whether they are willing to do a regional deal is the question mrna vaccines instruct ourselves to make a spike protein to fight covert 19. australia is already getting 40 million doses of fisa and biointex messenger rna vaccine plus 85 million booster shots it uses material from 86 suppliers in 19 different countries crucially fisa controls its supply chain and owns the rights to make its jab the vaccines are manufactured in europe and america and pfizer is ruling out manufacturing its vaccine here either directly or through partnerships they’ve been putting hundreds of millions of dollars into the know-how and their capability to deliver these as products and they’re going to want to protect that from a commercial point of view australia is also buying moderna’s vaccine which isn’t approved here yet the company relies on third-party manufacturers and the american conglomerate recently registered an entity here moderna australia the discussions with moderna which have been ongoing now for some time for some considerable time moderna wouldn’t comment on its plans for australian manufacturing the only short-term solution is probably modern making their vaccine under license that could be done by a few companies it could certainly be done by csl i’m confident it can be done by idt as well but even that won’t happen anytime soon in that case the time frame would be potentially 12 to 18 months but i think there’s others in my team that would say two to three years csl is the only australian company that’s currently making a cover jab here it’s making 50 million doses of the viral vector vaccine astrazeneca under a tech transfer agreement csl wouldn’t say what vaccine their latest mrna proposal involves lowena bio and viacena have both told the business that they’re not partnering with pfizer or moderna both have undisclosed partners which are still in trial phase we expect to be able to go from the start of the project to having registered vaccine approved by the tga out the door within two years colin putin also has a vaccine that’s about to go into clinical trials and is tied to idt’s proposal it’s probably going to be particularly useful for booster vaccines against variants of concern the victorian government is also injecting 50 million dollars into producing mrna vaccines here experts say that booster shots and long-term supply is where the opportunity lies but they urge us not to get too focused on one sort of vaccine for all the hype around mrna there is other types like astrazeneca and novovax which our government has ordered pending approval absolutely critical to have a whole range of vaccine solutions and potential solutions for covet 19. a sentiment that we now only know too well
rn

Pfizer rules out mRNA COVID vaccine manufacturing in Australia

rn

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *